[go: up one dir, main page]

GB1233055A - - Google Patents

Info

Publication number
GB1233055A
GB1233055A GB1233055DA GB1233055A GB 1233055 A GB1233055 A GB 1233055A GB 1233055D A GB1233055D A GB 1233055DA GB 1233055 A GB1233055 A GB 1233055A
Authority
GB
United Kingdom
Prior art keywords
nucleus
ingredient
retarding
active ingredient
outer layers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GB1233055A publication Critical patent/GB1233055A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B41/00—After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone
    • C04B41/45—Coating or impregnating, e.g. injection in masonry, partial coating of green or fired ceramics, organic coating compositions for adhering together two concrete elements
    • C04B41/50—Coating or impregnating, e.g. injection in masonry, partial coating of green or fired ceramics, organic coating compositions for adhering together two concrete elements with inorganic materials
    • C04B41/5025—Coating or impregnating, e.g. injection in masonry, partial coating of green or fired ceramics, organic coating compositions for adhering together two concrete elements with inorganic materials with ceramic materials
    • C04B41/5042—Zirconium oxides or zirconates; Hafnium oxides or hafnates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ceramic Engineering (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1,233,055. Delayed release tablets. LES LABORATOIRES DAUSSE. 14 June, 1968 [15 June, 1967], No. 28459/68. Heading A5B. Tablets comprise a nucleus and at least two outer layers, the nucleus and all the outer layers containing the active ingredient and a retarding ingredient to delay release of the active ingredient from the nucleus and layers after administration thereof, the nature and proportion of retarding ingredient being such that the rate of release of the active ingredient is different in the nucleus and each layer and increases from the nucleus outwards. Optionally the tablets may also comprise an outermost coating containing no active ingredients or retarding ingredients, e.g. sugar coatings. The retarding ingredient may be gum-lac, stearic acid or a salt or ester thereof, white wax, Carnauba wax, a polyethylene glycol, sodium dioctylsulphosuccinate, or cellulose acetophthlate. The rate of release of the active ingredient may be controlled by varying the proportion of retarding ingredient present in the nucleus and outer layers or by having the nucleus more highly compressed than the outer layers and each layer more highly compressed than any layer enclosing it. The active ingredient may comprise papaverine hydrochchloride, ethoxazorutin (mono-morpholinylethyl ether of rutin) and ascorbic acid.
GB1233055D 1967-06-15 1968-06-14 Expired GB1233055A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR110534A FR1545612A (en) 1967-06-15 1967-06-15 Tablet manufacturing process

Publications (1)

Publication Number Publication Date
GB1233055A true GB1233055A (en) 1971-05-26

Family

ID=8633106

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1233055D Expired GB1233055A (en) 1967-06-15 1968-06-14

Country Status (10)

Country Link
BE (1) BE716530A (en)
DE (1) DE1767765A1 (en)
ES (1) ES355054A1 (en)
FR (1) FR1545612A (en)
GB (1) GB1233055A (en)
IL (1) IL30165A (en)
IT (1) IT954035B (en)
LU (1) LU56264A1 (en)
NL (1) NL151902B (en)
SU (1) SU458966A3 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4059686A (en) * 1974-09-24 1977-11-22 Nippon Kayaku Kabushiki Kaisha Pharmaceutical preparation for oral cavity administration
US4289795A (en) * 1975-11-17 1981-09-15 Aktiebolaget Hassle Method for preparing preparations having controlled release of an active component
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5213807A (en) * 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076804A (en) * 1975-07-18 1978-02-28 Abbott Laboratories Erythromycin therapy
DK62184D0 (en) * 1984-02-10 1984-02-10 Benzon As Alfred DIFFUSION COATED POLYDEPOT PREPARATION
SE9402431D0 (en) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
PT1078628E (en) * 1994-07-08 2009-01-27 Astrazeneca Ab DOSAGE FORM IN TABLETS WITH MULTIPLE UNITS
EP1836665B1 (en) 2004-11-19 2013-01-16 GlaxoSmithKline LLC Method for customized dispensing of variable dose drug combination products for individualizing of therapies

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4059686A (en) * 1974-09-24 1977-11-22 Nippon Kayaku Kabushiki Kaisha Pharmaceutical preparation for oral cavity administration
US4289795A (en) * 1975-11-17 1981-09-15 Aktiebolaget Hassle Method for preparing preparations having controlled release of an active component
US4341759A (en) * 1975-11-17 1982-07-27 Aktiebolaget Hassle Granule having controlled release properties
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5213807A (en) * 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin

Also Published As

Publication number Publication date
ES355054A1 (en) 1969-11-16
NL6808312A (en) 1968-12-16
FR1545612A (en) 1968-11-15
IL30165A (en) 1973-04-30
IT954035B (en) 1973-08-30
IL30165A0 (en) 1968-08-22
SU458966A3 (en) 1975-01-30
DE1767765A1 (en) 1972-03-30
NL151902B (en) 1977-01-17
BE716530A (en) 1968-11-04
LU56264A1 (en) 1968-09-23

Similar Documents

Publication Publication Date Title
GB1233055A (en)
IE32612B1 (en) Pharmaceutical composition
IE34623L (en) Nitrofuryl-pyrazolopyrimidinones
IL30329A0 (en) New 13beta-alkyl-9beta,10alpha-pregnanes,methods of producing the same,pharmaceutical compositions comprising the new compounds as an active ingredient and a method of producing these compositions
GB1276089A (en) Pharmaceutical preparations
IL30307A0 (en) Novel derivatives of acetic acid,their preparation and pharmaceutical compositions containing them
GB1139869A (en) Improvements in or relating to tablets
IL34086A (en) 1-aryl-1,2,3-triazole-4-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
GB1235529A (en) Composition for mucolysis
IL30181A0 (en) 1-(substituted phenoxy)-2-hydroxy-3-tertiary butylaminopropanes,their preparation and pharmaceutical compositions containing them
GB1125924A (en) Organic bismuth derivative
IE34386B1 (en) Pharmaceutical compositions
GB1417323A (en) Physiologically active xanthine compounds and compositions containing them
FR1604555A (en) Antiviral preparations containing elanolic acid derivatives
GB1226555A (en)
CA762946A (en) Preparation of stannogluconic acid and compositions thereof
CA768658A (en) Method for preparation of 2,2'-thiobis (6-cumyl-p-cresol)
AU440336B2 (en) Derivatives of dialkylcysteines, and related compounds, preparation thereof, and compositions containing same
GB1454872A (en) Anticonvulsant
AU425947B2 (en) 5- substituted and 5- and 6- substituted 2- naphthyl acetic acid derivatives and compositions and methods of preparation thereof
AU3839868A (en) Preparation of nonprotein nitrogenous compositions
CA761475A (en) Preparation of 3,5-dibromosalicylic acid
GB1211649A (en) Pharmacologically effective substance and process for isolating it
CA758079A (en) Preparation of cyanuric acid
CA762952A (en) Anti-parasitically active hexachlorophene derivatives, compositions containing them, and methods of preparing both

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee